TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with 12 drug candidates, including Core Product TY-9591, seven products in the clinical stage, and four products in the preclinical stage or early clinical development stage.
2017
153
Last FY Revenue $14K
LTM EBITDA -$45.1M
$989M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TYK Medicines has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$45.1M.
In the most recent fiscal year, TYK Medicines achieved revenue of $14K and an EBITDA of -$44.1M.
TYK Medicines expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See TYK Medicines valuation multiples based on analyst estimatesLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue | n/a | XXX | $14K | XXX | XXX | XXX |
Gross Profit | n/a | XXX | $2K | XXX | XXX | XXX |
Gross Margin | n/a | XXX | 13% | XXX | XXX | XXX |
EBITDA | -$45.1M | XXX | -$44.1M | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | -323394% | XXX | XXX | XXX |
EBIT | -$50.8M | XXX | -$40.4M | XXX | XXX | XXX |
EBIT Margin | n/a | XXX | -296073% | XXX | XXX | XXX |
Net Profit | -$57.0M | XXX | -$49.3M | XXX | XXX | XXX |
Net Margin | n/a | XXX | -361640% | XXX | XXX | XXX |
Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, TYK Medicines's stock price is HKD 22 (or $3).
TYK Medicines has current market cap of HKD 8.0B (or $1.0B), and EV of HKD 7.8B (or $989M).
See TYK Medicines trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$989M | $1.0B | XXX | XXX | XXX | XXX | $-0.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, TYK Medicines has market cap of $1.0B and EV of $989M.
TYK Medicines's trades at 72562.1x EV/Revenue multiple, and -22.4x EV/EBITDA.
Equity research analysts estimate TYK Medicines's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TYK Medicines has a P/E ratio of -19.7x.
See valuation multiples for TYK Medicines and 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
EV (current) | $989M | XXX | $989M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | 72562.1x | XXX | XXX | XXX |
EV/EBITDA | -24.0x | XXX | -22.4x | XXX | XXX | XXX |
EV/EBIT | -21.3x | XXX | -24.5x | XXX | XXX | XXX |
EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
P/E | -19.7x | XXX | -20.8x | XXX | XXX | XXX |
EV/FCF | -19.1x | XXX | -20.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTYK Medicines's revenue per employee in the last FY averaged $0K, while opex per employee averaged $0.3M for the same period.
TYK Medicines's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TYK Medicines's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for TYK Medicines and other 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | n/a | XXX | 7085% | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | -323394% | XXX | XXX | XXX |
EBITDA Growth | -31% | XXX | n/a | XXX | XXX | XXX |
Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | $0K | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | 220043% | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 296086% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TYK Medicines acquired XXX companies to date.
Last acquisition by TYK Medicines was XXXXXXXX, XXXXX XXXXX XXXXXX . TYK Medicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free TrialWhen was TYK Medicines founded? | TYK Medicines was founded in 2017. |
Where is TYK Medicines headquartered? | TYK Medicines is headquartered in Hong Kong. |
How many employees does TYK Medicines have? | As of today, TYK Medicines has 153 employees. |
Is TYK Medicines publicy listed? | Yes, TYK Medicines is a public company listed on HKG. |
What is the stock symbol of TYK Medicines? | TYK Medicines trades under 02410 ticker. |
When did TYK Medicines go public? | TYK Medicines went public in 2024. |
Who are competitors of TYK Medicines? | Similar companies to TYK Medicines include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of TYK Medicines? | TYK Medicines's current market cap is $1.0B |
Is TYK Medicines profitable? | Yes, TYK Medicines is EBITDA-positive (as of the last 12 months). |
What is the current EBITDA of TYK Medicines? | TYK Medicines's last 12 months EBITDA is -$45.1M. |
What is the current EV/EBITDA multiple of TYK Medicines? | Current EBITDA multiple of TYK Medicines is -24.0x. |
What is the current FCF of TYK Medicines? | TYK Medicines's last 12 months FCF is -$56.9M. |
What is the current EV/FCF multiple of TYK Medicines? | Current FCF multiple of TYK Medicines is -19.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.